
Sign up to save your podcasts
Or


Inside the OLIO Clinical Trial: What You Need to Know
OLIO is an immunotherapy clinical trial that is examining whether the addition of olaparib to standard chemotherapy, with or without durvalumab, will improve outcomes for young, pre-menopausal women with high-risk, early breast cancer.
Dr Stephen Luen is the Study Chair of the OLIO clinical trial, and we spoke to him about the aim of this research, how it might improve patient outcomes, and his hopes for the future of breast cancer research.
Like this episode? Follow Breast Cancer Trials on Social Media:
Guest: Dr Stephen Luen
Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about clinical trials research.
Find out more: www.breastcancertrials.org.au
By Breast Cancer TrialsInside the OLIO Clinical Trial: What You Need to Know
OLIO is an immunotherapy clinical trial that is examining whether the addition of olaparib to standard chemotherapy, with or without durvalumab, will improve outcomes for young, pre-menopausal women with high-risk, early breast cancer.
Dr Stephen Luen is the Study Chair of the OLIO clinical trial, and we spoke to him about the aim of this research, how it might improve patient outcomes, and his hopes for the future of breast cancer research.
Like this episode? Follow Breast Cancer Trials on Social Media:
Guest: Dr Stephen Luen
Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about clinical trials research.
Find out more: www.breastcancertrials.org.au